Provenge
information and resources from the National Cancer Institute
NCI Thesaurus | Provenge
(Other name for: APC8015 vaccine)NCI Thesaurus | Provenge
(Other name for: APC8015 vaccine)
|
|
|
|
news articles
Body, Heal Thyself Mar 26, 2006
Chemical & Engineering News The company is preparing a Biologics License Application (BLA) for Provenge, which has been granted fast-track status by the Food & Drug Administration for use ...
Dendreon Names Christopher Lockett Head of Government Affairs Mar 23, 2006
Yahoo! News (press release) ...for managing Dendreon's relationships with local, state and federal government officials focusing initially on activities related to PROVENGE® (sipuleucel-T ...
Dendreon Names Mark Frohlich Vice President of Clinical Affairs Mar 16, 2006
PR Newswire (press release), ...in the public and private sectors, will focus on the completion of the clinical section of the Biologics License Application (BLA) for PROVENGE(R), which the ...
Analysis: Oncophage comes up short Mar 24, 2006
United Press International Paul Latta, an analyst with McAdams Wright Ragen, told UPI he thought Dendreon's cancer vaccine Provenge would ultimately be approved by the Food and Drug ...
Dendreon Reports Fourth Quarter and Year End 2005 Financial ... Mar 13, 2006
PR Newswire (press release), ..."In 2005, Dendreon continued to make significant strides toward the commercialization of PROVENGE," said Mitchell H. Gold, MD, president and chief executive ...
Manufacturing contract for world-first cancer vaccine Mar 13, 2006
In-PharmaTechnologist.com, ...the world. If approved, Dendreon's Provenge (sipuleucel-T) will be the first cancer vaccine ever to reach the market. The product ...
Dendreon Names Ernest Bognar General Manager of Hanover, NJ ... Mar 7, 2006
PharmaLive.com (press release), Dendreon is currently developing this facility to meet the anticipated clinical and commercial manufacturing needs for PROVENGE(R) (sipuleucel-T) and its other ...
The Overall Market for Cancer Treatments is Expected to Expand Due ... Mar 21, 2006
Genetic Engineering News, Although some companies are succeeding with their development of an autologous vaccine (such as Dendreon's Provenge), we anticipate that the use of autologous ...
Diosynth Biotechnology Enters Long-Term Commercial Supply ... Mar 2, 2006
International News Service, ...into a long-term commercial supply agreement with Dendreon Corporation for the manufacture of the recombinant antigen component of PROVENGE(R) (sipuleucel-T ...
Dendreon names Bognar manager of New Jersey facility Mar 7, 2006
Reliable Plant Magazine, ...in Hanover, NJ Dendreon is currently developing this facility to meet the anticipated clinical and commercial manufacturing needs for PROVENGE (sipuleucel-T ...
Diosynth Biotechnology Enters Long-Term Commercial Supply ... Mar 2, 2006
PR Newswire (press release), ...term commercial supply agreement with Dendreon Corporation (Nasdaq: DNDN) for the manufacture of the recombinant antigen component of PROVENGE(R) (sipuleucel-T ...
Diosynth wins contract, will do work at RTP Mar 2, 2006
Raleigh Triangle Business Journal, Diosynth initially will manufacture the recombinant antigen component of Dendreon's Provenge at its Research Triangle Park facility, where Diosynth currently ...
Dendreon Posts Wider Than Expected Q4 Loss - Update Mar 13, 2006
Trading Markets, Looking ahead to fiscal 2006, the company expects to submit to the FDA, the biologic license application for its prostate cancer drug PROVENGE, in the second ...
Akzo Nobel Announces Supply Agreement For Diosynth Mar 8, 2006
PharmaLive.com (press release), ...into a long-term commercial supply agreement with Dendreon Corporation for the manufacture of the recombinant antigen component of PROVENGE®, Dendreon’s ...
Dendreon's Q4, 2005 losses grow Mar 14, 2006
Bizjournals.com, At that time, company officials said they'll focus their efforts on bringing the company's prostate cancer drug, Provenge, to the commercial market. ...
Dendreon "buy," target price reduced Mar 16, 2006
newratings.com ...the new manufacturing facility at New Jersey, rise in clinical trial costs and infrastructure costs related to the commercialisation of Provenge, the analysts ...
Dendreon to Webcast Presentation at Invest Northwest Mar 17, 2006
Yahoo! News (press release) ...response. PROVENGE® (sipuleucel-T) is Dendreon's lead active cellular immunotherapy in Phase 3 development for prostate cancer. ...
Dendreon 4Q Loss Misses Street View Mar 13, 2006
Houston Chronicle, Revenue was down to $37,000 from $75,000 the year before, as the company continues to seek commercialization of its flagship drug, Provenge. ...
Business Doings Mar 15, 2006
News & Observer, Diosynth Biotechnology made a long-term commercial agreement with Dendreon Corp. to manufacture Provenge, Dendreon's immunotherapy for prostate cancer. ...
FDA Agrees to Special Protocol Assessment Amendment to D9902B ' ... Nov 29, 2005
Yahoo! News (press release) FDA) under the Special Protocol Assessment (SPA) procedure to amend the design of its ongoing Phase 3 (D9902B) clinical trial of PROVENGE® (sipuleucel-T), the ...
Dendreon to offer 10 million shares Nov 29, 2005
Seattle Times, The Seattle biotechnology company plans to file for approval of its experimental prostate-cancer therapy, Provenge, next year. Funds ...
ViroPharma Prices $150M Offer To Add To Capital, Pay Off Debt Dec 7, 2005
BioWorld Online (subscription), ...is bringing in $45 million to support its biologics license application for its prostate cancer drug, Provenge, as well as early commercialization activities. ...
Dendreon plans 10M share sale Nov 29, 2005
Puget Sound Business Journal, Separately, the company said the US Food and Drug Administration has approved changes to an ongoing phase three clinical trial of its Provenge prostate cancer ...
(PRN) - Synaptics to Present at Upcoming Investor Conferences ... ... Nov 29, 2005
Bolsamania.com, ...to 2008 ... [+. PRN) - FDA Agrees to Special Protocol Assessment Amendment to D9902B 'IMPACT' Study of PROVENGE ... [+. PRN) - The ...
|
|
